Abstract 1062P
Background
Some studies, including a recent meta-analysis, observed that the circadian rhythm of immune cell’s proliferation and destruction may influence progression-free and overall survival in metastatic cancer treated with immunotherapy (IO). This study aims to assess whether such differences persist in patients with locally advanced non-small-cell lung cancer (NSCLC) undergoing radical concurrent chemo/radiotherapy (CRT) and IO consolidation depending on the time of day of IO administration.
Methods
For this study, all the histologically confirmed patients with irresectable NSCLC PDL1 >1% treated with radical concurrent CRT and IO consolidation (PACIFIC protocol) from 2018 to 2023 in our hospital were included. These patients were categorized depending on the median time of IO administration in two groups: morning (before 3pm) or afternoon group (after 3 pm).
Results
A total of 41 patients were identified. The mean age was 65.4 years (range 45-78) of which 34 were males (82.9%) and 24 presented squamous cell carcinoma histology (58.5%). The morning group included 28 patients (68%), receiving 50% or more doses of IO before 3 pm, while the afternoon group included 13 patients (32%), receiving less than 50% of doses before 3pm. Patients received a mean of 7.78 months (range 1-13) of consolidation IO after radical concurrent CRT. Progression-free survival (PFS) was significantly better in the morning group compared to the afternoon group. Median PFS is not achieved vs 13 months (p=0.017; Hazard Ratio 3.04, 95% CI 1.17-7.91, p=0.023). The 1-year PFS rates were 68.5% vs. 51.9% and mean PFS was 33 vs. 16.4 months. Overall survival (OS) favoured the morning group but did not reach statistical significance. Median OS 44 vs. 31 months (p=0.21; HR 1.97, 95% CI 0.68-5.74). The 1-year OS rates were 91.8% vs. 84.6%, and 3year OS rates were 66.4% vs 32.6%.
Conclusions
This retrospective analysis indicates that patients treated preferentially before 3pm exhibit a better disease control than those treated onwards. Preferential treatment in the morning may enhance disease control and improve OS. This encourages the release of a prospective clinical trial.
Clinical trial identification
CEIM code 2023.217; Approved on 07/11/2023.
Editorial acknowledgement
Legal entity responsible for the study
Institut Català d'Oncologia - Girona and IDIBGI.
Funding
IDIBGI.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
917P - Automatic characterization of spatial arrangement of tumor-infiltrating lymphocytes identifies oral cavity squamous cell carcinoma patients with poorer prognosis
Presenter: German Corredor
Session: Poster session 03
918P - Deciphering the molecular drivers behind locoregional progression, intratumoral heterogeneity, and clonal evolution in locally advanced head and neck cancer
Presenter: Gema Bruixola
Session: Poster session 03
919P - Predictive multi-omic signature in locally advanced laryngeal/hypopharyngeal (LH) squamous cell carcinoma (SCC) treated with induction chemotherapy (IC)
Presenter: Paolo Bossi
Session: Poster session 03
920P - Genomic landscape of head and neck cancer in Asia: A comprehensive meta-analysis of 1016 samples
Presenter: Sewanti Limaye
Session: Poster session 03
Resources:
Abstract
921P - Divergent fates: The ambiguous role of M2-like TAMs in oropharyngeal cancer
Presenter: Michael Saerens
Session: Poster session 03
922P - Genomic instability as a biomarker for advanced cancer of the head and neck
Presenter: Filippo Dall'Olio
Session: Poster session 03
923P - Tumor-informed ctDNA assay to predict recurrence in locally advanced SCCHN
Presenter: Natasha Honoré
Session: Poster session 03
924P - Claudin-1 (CLDN1) tight junction protein expression delineates distinct immune infiltrates in ascending (A) vs descending (D) subtypes of nasopharyngeal carcinoma: Potential implications for treatment selection
Presenter: Darren Wan-Teck Lim
Session: Poster session 03
925P - External validation of the CD8 radiomics signature as a prognostic marker in recurrent or metastatic head and neck cancer treated with nivolumab
Presenter: Laville Adrien
Session: Poster session 03
926P - Genetic alteration in olfactory neuroblastoma: Unraveling carcinogenesis mechanisms and chemotherapy resistance through whole exome sequencing analysis
Presenter: Haruhi Furukawa
Session: Poster session 03